GREENLAND MINES LTD Increase (Decrease) in Income Taxes Payable
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Income Taxes Payable of -$568.11 thousand for the 12-month period ending 2024-12-31, per its 10-K/A filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-14
- GREENLAND MINES LTD increase (decrease) in income taxes payable for the quarter ending 2024-12-31 was $0.00.
- GREENLAND MINES LTD increase (decrease) in income taxes payable for the quarter ending 2024-03-31 was -$101.10K, a 162.82% decline year-over-year.
- GREENLAND MINES LTD increase (decrease) in income taxes payable for the quarter ending 2023-03-31 was $160.95K.
- GREENLAND MINES LTD increase (decrease) in income taxes payable for fiscal 2024 was -$568.11K.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | -$568.11K 10-K/A · filed 2026-08-14 | ||
| 2024-09-30 | -$568.11K 10-Q · filed 2025-11-13 | |||
| 2024-03-31 | -$101.10K 10-Q · filed 2024-05-23 | |||
| 2023-03-31 | $160.95K 10-Q · filed 2024-05-23 | |||
| 2022-06-30 | $39.30K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |